1
|
Loganathan J, Cohen AC, Kaloupis GM, Harris C, Chronopoulos A, James V, Hamilton J, Green S, Wallis A, Morgan S, Dauer R, Gilfillan C, Dear AE. A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study). J Diabetes Complications 2022; 36:108188. [PMID: 35382966 DOI: 10.1016/j.jdiacomp.2022.108188] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Revised: 03/24/2022] [Accepted: 03/26/2022] [Indexed: 11/20/2022]
Abstract
BACKGROUND Liraglutide is an effective treatment for the management of type 2 diabetes mellitus (T2DM). In addition to glycemic control and potential cardioprotective effects, recent studies suggest a possible role for liraglutide in the inhibition of platelet reactivity, further attenuating atherothrombotic risk in patients with T2DM. We evaluated the in-vivo antiplatelet effect of liraglutide in T2DM patients without macrovascular disease or concurrent anti-platelet therapy. METHODS A double-blind, placebo-controlled pilot study of 16 T2DM patients, 51-69 y/o, (mean age 60.4 y/o, 63.0% male) randomised to receive liraglutide (1.8 mg/day) or placebo (saline) for 6 months was conducted. Platelet aggregation studies at baseline and after initiation of the study intervention: days 1, 7, and 14 and months 1, 3 and 6 were performed. RESULTS Liraglutide (n = 7) and placebo (n = 9) treated patients demonstrated normal platelet aggregation responses although transient and significant attenuation in maximum slope of platelet aggregation in response to collagen (p ≤ 0.05), arachidonic acid (p ≤ 0.05) and ADP (p ≤ 0.02) was observed in liraglutide compared to placebo treated patients in the first week. CONCLUSIONS In this pilot study of patients with T2DM liraglutide treatment was associated with a significant, early and transient decrease in maximum slope of platelet aggregation. The clinical significance of this effect is currently unknown and may warrant further investigation. CLINICAL TRIAL REGISTRATION NUMBER UTN 1111-1181-9567.
Collapse
Affiliation(s)
- Jayasree Loganathan
- Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia
| | - Adam C Cohen
- Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia
| | - Georgia M Kaloupis
- Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia
| | - Carolyn Harris
- Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia
| | | | - Vanessa James
- Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia
| | - Justin Hamilton
- Australian Centre for Blood Diseases, Monash University, Prahran, Melbourne, Victoria, Australia
| | - Sarah Green
- Alfred Pathology Service, Alfred Health, Alfred Hospital, Melbourne, Victoria, Australia
| | - Andrew Wallis
- Alfred Pathology Service, Alfred Health, Alfred Hospital, Melbourne, Victoria, Australia
| | - Susan Morgan
- Alfred Pathology Service, Alfred Health, Alfred Hospital, Melbourne, Victoria, Australia
| | - Raymond Dauer
- Department of Pathology, Eastern Health, Box Hill Hospital, Melbourne, Australia
| | - Christopher Gilfillan
- Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia; Department of Endocrinology, Eastern Health, Box Hill Hospital, Melbourne, Victoria, Australia
| | - Anthony E Dear
- Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.
| |
Collapse
|
3
|
Stimpfle F, Geisler T. Impact of tailored anti-P2Y12 therapies in acute coronary syndromes. Pharmacogenomics 2015; 16:493-9. [DOI: 10.2217/pgs.15.19] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Acute coronary syndromes are a major disease burden and the prognosis has improved over the last decades due to improvement of medical and interventional treatments. Novel P2Y12-ADP-receptor antagonists have been introduced into clinical treatment offering more potent and rapid onset of action with the downside of increased bleeding risk. This special report will focus on interindividual variability of antiplatelet drugs in the setting of acute coronary syndromes and the current impact and potential future of point-of-care testing to personalize therapy aiming to improve prognosis in acute coronary syndrome patients.
Collapse
Affiliation(s)
- Fabian Stimpfle
- University Hospital Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, Germany
| | - Tobias Geisler
- University Hospital Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, Germany
| |
Collapse
|